Pre-radiotherapy PSA progression is a negative prognostic factor in prostate cancer patients using 5‑alpha-reductase inhibitors-Reference-Cited by-同舟云学术

Pre-radiotherapy PSA progression is a negative prognostic factor in prostate cancer patients using 5‑alpha-reductase inhibitors

Published:2017-07-10 Issue:1 Volume:194 Page:17-22
ISSN:0179-7158
Container-title:Strahlentherapie und Onkologie
language:en
Short-container-title:Strahlenther Onkol

Author:

Taussky Daniel^ORCID,Piotte Julie,Zorn Kevin C.,Zanaty Marc,Krishnan Vimal,Lambert Carole,Bahary Jean-Paul,Beauchemin Marie-Claude,Barkati Maroie,Ménard Cynthia,Delouya Guila

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Radiology Nuclear Medicine and imaging

Link

http://link.springer.com/article/10.1007/s00066-017-1176-z/fulltext.html

Reference25 articles.

1. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N’Dow J, Nordling J, de la Rosette JJ, European Association of Urology (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64(1):118–140. doi: 10.1016/j.eururo.2013.03.004

2. Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Drager BJ, Schroder FH, Stenzl A, Tombal B, Wilt TJ, Wolk A (2014) Prevention and early detection of prostate cancer. Lancet Oncol 15(11):e484–492. doi: 10.1016/S1470-2045(14)70211-6

3. Schroder F, Bangma C, Angulo JC, Alcaraz A, Colombel M, McNicholas T, Tammela TL, Nandy I, Castro R (2013) Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS). Eur Urol 63(5):779–787. doi: 10.1016/j.eururo.2012.11.006

4. Unger JM, Till C, Thompson IM Jr., Tangen CM, Goodman PJ, Wright JD, Barlow WE, Ramsey SD, Minasian LM, Hershman DL (2016) Long-term consequences of Finasteride vs placebo in the prostate cancer prevention trial. J Natl Cancer Inst 108(12). doi: 10.1093/jnci/djw168

5. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349(3):215–224. doi: 10.1056/NEJMoa030660